Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Core Insights - Nuvalent, Inc. is set to present a poster on its novel HER2-selective inhibitor, NVL-330, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025 [1][2]. Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for cancer, aiming to address the limitations of existing treatments for clinically proven kinase targets [3]. - The company utilizes expertise in chemistry and structure-based drug design to create innovative small molecules that can overcome resistance, minimize adverse events, and target brain metastases [3]. - Nuvalent is advancing a pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3].